|0.3813||-0.0137||-3.47%||Vol 28.29K||1Y Perf -78.06%|
|Sep 22nd, 2023 15:59 DELAYED|
|- -||- -%|
|Target Price||6.75||Analyst Rating||Strong Buy 1.00|
|Potential %||1.67K||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 44.44|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★+ 43.39|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||1.05||Earnings Rating||—|
|Market Cap||13.93M||Earnings Date||14th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||14th Nov 2023|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||96.58K|
|Avg. Monthly Volume||114.58K|
|Avg. Quarterly Volume||1.70M|
Frequency Therapeutics Inc. (NASDAQ: FREQ) stock closed at 0.3813 per share at the end of the most recent trading day (a -3.47% change compared to the prior day closing price) with a volume of 28.29K shares and market capitalization of 13.93M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 47 people. Frequency Therapeutics Inc. CEO is David L. Lucchino.
The one-year performance of Frequency Therapeutics Inc. stock is -78.06%, while year-to-date (YTD) performance is -90.1%. FREQ stock has a five-year performance of %. Its 52-week range is between 0.3258 and 5.59, which gives FREQ stock a 52-week price range ratio of 1.05%
Frequency Therapeutics Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 1.53, a price-to-sale (PS) ratio of 5.42, a price to cashflow ratio of 28.20, a PEG ratio of -, a ROA of -50.69%, a ROC of -53.77% and a ROE of -74.83%. The company’s profit margin is -72.67%, its EBITDA margin is -890.20%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Frequency Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Frequency Therapeutics Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for Frequency Therapeutics Inc. is Strong Buy (1), with a target price of $6.75, which is +1 670.26% compared to the current price. The earnings rating for Frequency Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Frequency Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Frequency Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 23.25, ATR14 : 0.05, CCI20 : -117.72, Chaikin Money Flow : -0.50, MACD : -0.04, Money Flow Index : 21.51, ROC : -15.08, RSI : 29.52, STOCH (14,3) : 9.37, STOCH RSI : 0.38, UO : 22.14, Williams %R : -90.63), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Frequency Therapeutics Inc. in the last 12-months were: Loose Christopher R. (Sold 4 931 shares of value $2 792 ), Lucchino David L. (Sold 9 817 shares of value $5 557 ), Mitrano Richard J. (Sold 832 shares of value $469 ), Richard J. Mitrano (Sold 3 738 shares of value $2 277 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.